

DIRECTORS AND SENIOR MANAGEMENT

BOARD OF DIRECTORS

Our Board is the primary decision-making body of our Company, setting fundamental business strategies and policies for the management and operation of our business and monitoring their implementation. Our Board will consist of nine Directors, comprising three executive Directors, three non-executive Directors and three independent non-executive Directors upon the [REDACTED]. All of our executive Directors, non-executive Directors and independent non-executive Directors are elected to serve an initial term of three years, which are renewable upon re-election and/or re-appointment.

The following table sets out certain information of our Directors:

Name	Age	Position(s)	Principal roles and responsibilities	Date of joining our Group	Date of appointment as Director	Relationship with other Directors senior management members
Executive Directors						
Dr. Wang. . . .	46	Chairman, executive Director and chief executive officer	Formulating our strategic development plans, and supervising our overall drug development and daily operation	May 2014	May 2014	None
Dr. Zhang Guiping (張貴平博士) .	42	Executive Director and vice president of our R&D department	Managing and supervising our R&D activities	July 2020	October 2020	None
Mr. Li Jiapeng (李家鵬先生) .	42	Executive Director and vice president of our R&D department	Managing and supervising our R&D activities	March 2019	February 2020	None
Non-executive Directors						
Mr. Ai Xing (艾興先生). .	60	Non-executive Director	Supervising our overall development	December 2022	December 2022	None
Ms. Shen Qin (沈琴女士). .	49	Non-executive Director	Supervising our overall development	July 2022	July 2022	None
Mr. Chen Gao (陳杲先生). .	33	Non-executive Director	Supervising our overall development	June 2020	June 2020	None
Independent Non-executive Directors						
Dr. Cheng Zengjiang (程增江博士) .	60	Independent non-executive Director	Supervising and providing independent judgement to our Board	13 January 2026	Immediately prior to the [REDACTED]	None
Ms. Zhu Zhaoxia (朱朝霞女士) .	50	Independent non-executive Director	Supervising and providing independent judgement to our Board	13 January 2026	Immediately prior to the [REDACTED]	None
Mr. Chai Jinshan (柴金山先生) .	50	Independent non-executive Director	Supervising and providing independent judgement to our Board	13 January 2026	Immediately prior to the [REDACTED]	None

DIRECTORS AND SENIOR MANAGEMENT

Note:

Save for the above, Mr. Zhou Baolei (周寶磊) was appointed as our executive Director on 28 May 2018 and resigned on 31 December 2024. Ms. Ji Feihong (姬飛虹), who was appointed as our executive Director on 30 December 2022. Mr. Liu Guidong (劉桂東), who was appointed as our executive Director on 31 December 2024. Mr. Lu Gang (陸剛), who was appointed as our non-executive Director on 29 March 2023, all of whom have tendered their resignation with effect immediately prior to the [REDACTED]. As confirmed by our Company, the resignations of Mr. Zhou Baolei, Ms. Ji Feihong, Mr. Liu Guidong and Mr. Lu Gang are due to their personal career arrangements. Each of them has no disagreement with us or our Board, and there are no matters relating to their resignations that need to be brought to the attention of the Stock Exchange.

DIRECTORS

Executive Directors

Dr. Wang, aged 46, is the Chairman of our Board, an executive Director, our chief executive officer and one of the members of our Group of Controlling Shareholders. Dr. Wang is responsible for formulating our strategic development plans, and supervising our overall drug development and daily operation. Dr. Wang is the founder of our Company, the chairman of our Nomination Committee and a member of our Remuneration Committee.

Dr. Wang has more than a decade of experience in the pharmaceutical industry and corporate governance realm. Dr. Wang also engaged in postdoctoral research in basic medicine at Zhejiang University (浙江大學) from March 2012 to September 2015 after he completed his doctorate studies.

Dr. Wang also holds the following positions with the other members of our Group and has been primarily responsible for these companies’ decision-making:

- an executive director and the manager of Haosheng Shanghai,
- an executive director and the manager of Genhouse Guangzhou,
- an executive director and the manager of Genhouse Yancheng, and
- the responsible person for our Beijing branch company.

Dr. Wang obtained his bachelor’s degree in clinical medicine from Anhui Medical University (安徽醫科大學) in June 2004. Dr. Wang obtained his doctorate’s degree in pharmacology from Shanghai Institute of Materia Medica, Chinese Academy of Sciences (中國科學院上海藥物研究所) in July 2011.

Dr. Wang was named as a talent for the fourth batch of the National “Ten Thousand Talent Programme” (第四批國家“萬人計劃”) and a talent for “Innovation Progression for Technology and Entrepreneurship” (創新人才推進計劃科技創新人才). Dr. Wang was also named for the “Innovation and Entrepreneurship Talent (Entrepreneurial Category)” (“雙創人才”創業類); and named as a talent for the sixth batch of the “Jiangsu Provincial ‘333’ High-Level Talent Training Project” (江蘇省第六期“333”高層次人才). Dr. Wang has also been honoured as one of the “Suzhou Top 10 Role Models of the Era” (蘇州市十佳時代新人), and has also been awarded as a “High-level Leading Talent” (高層次領軍人才) under the “Jinji Lake Talent Plan” (金雞湖人才計劃).

Dr. Wang was an executive director and the legal representative of the following dissolved companies incorporated in the PRC. The relevant details are as follows:

Company name	Nature of business before dissolution	Position	Responsibility	Reason for dissolution	Current status and date of dissolution
Luoyang Qin hao Biotechnology Co., Ltd. (洛陽勤浩生物科技股份有限公司) (“ Luoyang Genhouse ”)	Biomedical technology services	Legal representative, executive director and general manager	Supervising our overall drug development and daily operation	Cessation of business	Voluntarily deregistered on 12 June 2020
Shanghai Kai hao Pharmaceutical Technology Co., Ltd. (上海凱浩醫藥科技有限公司) (“ Shanghai Kaihao ”).	Pharmaceutical-chemical and biotechnological technical services	Legal representative, executive director	Supervising overall drug development and daily operation	Cessation of business	Voluntarily deregistered on 10 October 2014

DIRECTORS AND SENIOR MANAGEMENT

Company name	Nature of business before dissolution	Position	Responsibility	Reason for dissolution	Current status and date of dissolution
Genhouse HK.	Corporation (法團)	Director	Supervising overall drug development and daily operation	Streamlining the structure of our Group	Has been dissolved as of the Latest Practicable Date

Dr. Wang confirmed that, to the best of his knowledge, (i) Luoyang Genhouse, as our subsidiary, was originally primarily engaged in the provision of technical services to external parties. However, as we focused on R&D activities of innovative drugs, the business direction of Luoyang Genhouse was no longer aligned with our long-term strategy, and Dr. Wang therefore decided to cease its business. Shanghai Kaihao was established in Shanghai. Following the establishment of our Company in Suzhou, Dr. Wang decided to cease the business of Shanghai Kaihao to consolidate resources and optimise our management structure. As for Genhouse HK, it was originally established to undertake our then-planned overseas R&D projects. Due to subsequent strategic adjustments to such projects, there was no longer a need to maintain an overseas entity, and Dr. Wang therefore ceased all business activities of Genhouse HK; (ii) each of the aforesaid deregistered companies was solvent immediately prior to its deregistration and had no outstanding claim or liabilities arising from any material non-compliance incidents; (iii) he has not received any notification in respect of penalty, action or proceeding from the PRC authorities as a result of the deregistration; (iv) he is not aware of any actual or potential claim which has been or will be made against him as a result of the deregistration and (v) there was no judgments or findings of fraud, dishonesty, any misconduct or wrongful act on Dr. Wang’s part in connection with the dissolution of the above companies and the dissolution of the above companies was due to the above companies’ own voluntary decision to cease business.

Dr. Wang also held the office on the following company incorporated in the PRC prior to the revocation of its business licence and the relevant details are as follows:

Company name	Nature of business before revocation of business licence	Position	Responsibility	Reason for revocation of business licence	Current status and date of revocation of business licence
Shanghai Yanhai Industry Co., Ltd. (上海岩海實業有限公司) (“Shanghai Yanhai”)	Sales of mechanical devices	Director	Providing strategic guidance	<i>Note</i>	Compulsorily liquidated followed by revocation of business licence on 15 June 2019

Note: The company was deregistered as it was inactive with no substantial business operation. Prior to its respective deregistration, the business licence of the company had been revoked as the company had no substantial business operation and had omitted the requirement of annual inspection.

Dr. Wang confirmed that, to the best of his knowledge, (i) as the principal shareholders and actual operator of Shanghai Yanhai had other entrepreneurial plans, Shanghai Yanhai remained inactive with no substantial business operations until it was compulsorily liquidated and its business licence was revoked. In the course of this process, there was no wrongful act on Dr. Wang part leading to the revocation of business licence pertinent to Shanghai Yanhai; (ii) the aforesaid company was solvent immediately prior to its revocation of business licence or deregistration and had no outstanding claim or liabilities arising from any material non-compliance incidents; (iii) he has not received any notification in respect of penalty, action or proceeding from the PRC authorities as a result of the revocation of business licence or deregistration; and (iv) he is not aware of any actual or potential claim which has been or will be made against him as a result of the revocation of business licence or deregistration.

Dr. Zhang Guiping (張貴平), aged 42, is an executive Director and the vice president of our R&D department, responsible for managing and supervising our R&D activities.

Dr. Zhang has more than a decade of experience in pharmaceutical industry. Prior to joining our Company, Dr. Zhang served as the director of Shanghai Simcere Pharmaceutical Co., Ltd. (上海先聲藥物研究有限公司), Dr. Zhang then served as the project manager of Shenzhen Salubris Pharmaceuticals Co., Ltd. (深圳信立泰藥業股份有限公司), a company listed on the Shenzhen Stock Exchange (stock

DIRECTORS AND SENIOR MANAGEMENT

code: 002294). Dr. Zhang conducted his research studies at the College of Pharmacy, University of Illinois in Chicago, the United States from March 2016 to March 2018. From May 2018 to March 2019, Dr. Zhang worked as a principal scientist of Starwise Therapeutics LLC, the United States. Dr. Zhang returned to China and joined Bontac Bio-engineering (Shenzhen) Co., Ltd (邦泰生物工程(深圳)有限公司) as the deputy director of the R&D Centre and served the company from May 2019 to June 2020.

In addition the aforesaid, Dr. Zhang also possesses academic teaching experience with his tenure as a current mentor for postgraduate students at the School of Agriculture and Biology, Shanghai Jiao Tong University (上海交通大學) with effect from June 2023.

Dr. Zhang is currently serving as the project leader of the “Jiangsu Provincial Key R&D Programme” (江蘇省科技重大專項項目). Dr. Zhang has been recognised as a “Jiangsu Double-Innovation Talent” (江蘇省雙創人才), a “Suzhou Innovation and Entrepreneurship Leading Talent” (姑蘇創新創業領軍人才) and a “Suzhou Industrial Park Innovation Leading Talent (Class A)” (蘇州工業園區創新領軍人才(A類)), respectively. Notably, Dr. Zhang is one of the core members of the “2023 Gusu Major Innovation Team” (2023姑蘇重大創新團隊), has been recognised as a “Shenzhen Overseas High-Level Talent (C Class)” (廣東省深圳市海外高層次人才(C類)) and a “High-level Comprehensive Talent of Bao'an District of Shenzhen City” (深圳市寶安區高層次綜合類人才), respectively. Dr. Zhang also serves as a peer reviewer for several international and domestic academic journals, including *Science Journal of Chemistry*, *Journal of Medicinal Chemistry*, *Organic Process Research & Development*, and *Bioorganic & Medicinal Chemistry Letters*.

Dr. Zhang obtained his bachelor's degree in chemical engineering and technology from Huazhong University of Science and Technology (華中科技大學) in June 2006. Dr. Zhang obtained his doctorate's degree in medicinal chemistry from Shanghai Institute of Materia Medica, Chinese Academy of Sciences (中國科學院上海藥物研究所) in January 2012.

Mr. Li Jiapeng (李家鵬先生), aged 42, is our executive Director and the vice president of our R&D department, responsible for supervising our R&D activities.

Mr. Li has more than a decade of experience in the pharmaceutical industry. From 2012 to 2019, Mr. Li successively worked at Shanghai Standard Biotech Co., Ltd. (上海詩丹德生物技術有限公司), Shanghai Aibo Pharmaceutical Technology Co., Ltd. (上海愛博醫藥科技有限公司), and Shanghai Baoheng Hongkang Biotechnology Co., Ltd. (上海寶恒泓康生物技術有限公司).

Mr. Li obtained his bachelor's degree in biotechnology from Nanjing University (南京大學) in July 2007, and graduated from Shanghai Institute of Materia Medica, Chinese Academy of Sciences (中國科學院上海藥物研究所) in July 2012.

Mr. Li obtained his Pharmacist Qualification Certificate (執業藥師職業資格證書) issued by Shanghai Municipal Human Resources and Social Security Bureau (上海市人力資源和社會保障局) in January 2014. Mr. Li was recognised as a “Suzhou Innovative Entrepreneurship Leading Talent (second batch)” (第二批姑蘇創新創業領軍人才) by Suzhou People's Government (蘇州市人民政府) in December 2019.

Non-executive Directors

Mr. Ai Xing (艾興先生), aged 60, is our non-executive Director. Mr. Ai joined us in December 2022 and is responsible for supervising our overall development.

Mr. Ai served as the general manager of Shenzhen Capital Group Co., Ltd. (Shanghai Branch) (深圳市創新投資集團有限公司上海公司) from May 2008 to August 2008. From May 2009 to November 2025, Mr. Ai served as the general manager of Changzhou Hongtu Innovation and Entrepreneurship Investment Co., Ltd. (常州紅土創新創業投資有限公司). Since May 2009, Mr. Ai has been in the positions of the general manager and a director of Changzhou Wujin Hongtu Venture Capital Co., Ltd. (常州武進紅土創業投資有限公司).

Mr. Ai is also incumbent in the following companies: (i) a director of Rundong Pharmaceutical Research and Development (Shanghai) Co., Ltd. (潤東醫藥研發(上海)有限公司) since January 2015; (ii) a director of Shanghai Yinke E-Commerce Co., Ltd. (上海印克電子商務股份有限公司) since December 2015; (iii) a director of Shanghai Wujiu Information Technology Co., Ltd. (上海舞九信息科技有限公司) since January 2016; (iv) a director of Changzhou Yonganxing Hydrogen Energy

DIRECTORS AND SENIOR MANAGEMENT

Technology Co., Ltd. (常州永安行氢能科技有限公司) since June 2022; (v) a director of Shanghai Same Cell Technology Co., Ltd. (上海薩美細胞技術有限公司) since June 2022 and (vi) a director of Xiamen Xiangyang Yinke Food Co., Ltd. (廈門向陽印克食品有限公司) since September 2022.

Mr. Ai obtained his master’s degree in industrial economics from Shanghai University of Finance and Economics (上海財經大學) in 1993.

Mr. Ai was granted the fund practising qualification by the Asset Management Association of China (中國證券投資基金業協會) in July 2017.

Mr. Ai was the chairman of the board and the legal representative of the following company and the relevant details are as follows:

Company name	Nature of business before dissolution	Position	Responsibility	Reason for dissolution	Current status and date of dissolution
Shanghai Zhenghailong Enterprise Development Co., Ltd. (上海正海隆企業發展有限公司) (“Shanghai Zhenghailong”) . . .	Investment and asset management	Legal representative, the chairman of the board	Supervising daily operation	Cessation of business	Voluntarily deregistered on 14 September 2023
Kebisi Zhenjiang Fertiliser Co., Ltd. (科比斯鎮江肥業有限公司) (“Kebisi”)	Fertiliser manufacturing	Director	Providing strategic guidance	Cessation of business	Voluntarily deregistered on 7 December 2018
Metal Rabbit Games (Changzhou) Co., Ltd. (常州瑞虎網絡科技有限公司) (“Metal Rabbit”) . . .	Internet technology services	Director	Providing strategic guidance	Cessation of business	Voluntarily deregistered on 4 June 2018

Mr. Ai confirmed that, to the best of his knowledge, (i) Mr. Ai was the founder of Shanghai Zhenghailong. After he joined Shenzhen Capital, Mr. Ai decided to cease the business of Shanghai Zhenghailong due to his personal career planning. Nominated by Changzhou Hongtu Talent, Mr. Ai served as a director of Kebisi and Metal Rabbit but only provided strategic guidance and did not participate in the day-to-day operations of these two companies. Kebisi and Metal Rabbit subsequently ceased their business due to poor operating performance. During this period, there was no judgments or findings of fraud, dishonesty, any misconduct or wrongful act on Mr. Ai’s part in connection with the dissolution of Kebisi and Metal Rabbit. The dissolution of the above companies was due to the their own voluntary decision; (ii) each of the aforesaid deregistered companies was solvent immediately prior to its deregistration and had no outstanding claim or liabilities arising from any material non-compliance incidents; (iii) he has not received any notification in respect of penalty, action or proceeding from the PRC authorities as a result of the deregistration; and (iv) Mr. Ai is not aware of any actual or potential claim which has been or will be made against him as a result of the deregistration.

Mr. Ai also held the office in the following companies incorporated in the PRC prior to the revocation of their respective business licences and the relevant details are as follows:

Company Name	Nature of business before revocation of business licence	Position	Responsibility	Reason for revocation of business licence	Current status and date of revocation of business licence
Shanghai Xinyi Non-ferrous Foundry Co., Ltd (上海新藝有色鑄造有限公司) (“Shanghai Xinyi”)	Non-ferrous metals foundry	Legal representative, director	Providing strategic guidance	<i>Note</i>	Compulsorily liquidated followed by revocation of business licence in May 2024

DIRECTORS AND SENIOR MANAGEMENT

Company Name	Nature of business before revocation of business licence	Position	Responsibility	Reason for revocation of business licence	Current status and date of revocation of business licence
Shanghai Nan Zhiquan Industrial Co., Ltd. (上海南之泉實業有限公司) (formerly known as Makete Group Shanghai Industrial Co., Ltd. (麥科特集團上海實業有限公司)) (“Nanzhiquan”)	Investment and asset management	Vice chairman of the board	Providing strategic guidance	<i>Note</i>	Compulsorily liquidated followed by revocation of business licence on 19 April 2009
Shanghai Meifeinet Industrial Co., Ltd. (上海美飛內特實業有限公司) (“Meifeinet”).	Electronic equipment manufacturing	Supervisor	Providing strategic guidance	<i>Note</i>	Compulsorily liquidated followed by revocation of business licence on 19 December 2006

Note: The company was deregistered as it was inactive with no substantial business operation. Prior to its deregistration, the business licence of the company had been revoked as the company had no substantial business operation and had omitted the requirement of annual inspection.

Mr. Ai confirmed that, to the best of his knowledge, (i) Shanghai Xinyi, Nanzhiquan and Meifeinet were companies founded by friends of Mr. Ai. Mr. Ai was invited to provide strategic guidance to these companies but did not participate in their day-to-day operations and management. Upon joining Shenzhen Capital, Mr. Ai resigned from his positions at these three companies. The subsequent compulsory liquidation and deregistration of these three companies were not attributable to any act or omission on the part of Mr. Ai. During his tenure, there was no wrongful act on Mr. Ai’s part leading to the revocation of business licence pertinent to each of the aforesaid three companies; (ii) each of the aforesaid companies was solvent immediately prior to its revocation of business licence or deregistration and had no outstanding claim or liabilities arising from any material non-compliance incidents; (iii) he has not received any notification in respect of penalty, action or proceeding from the PRC authorities as a result of the revocation of business licence or deregistration; and (iv) he is not aware of any actual or potential claim which has been or will be made against him as a result of the revocation of business licence or deregistration.

Ms. Shen Qin (沈琴女士), aged 49, is our non-executive director. Ms. Shen joined us in July 2022 and is responsible for supervising our overall development.

In addition to her directorship with our Company, Ms. Shen is currently serving as a director of Hunan Vathin Medical Instrument Co., Ltd. (湖南省華芯醫療器械有限公司) since February 2022. Hunan Vathin Medical Instrument Co., Ltd is a medical technology company focusing on the field of single-use electronic endoscopes and minimally invasive specialised robotics, primarily engaged in the R&D, manufacturing, sales of minimally invasive surgical instruments including single-use bronchoscopes, ureterorenoscopes, and cystoscopes, etc. As its principal business is entirely different from that of our company, the business of Hunan Vathin Medical Instrument Co., Ltd. does not constitute direct or indirect competition with our business under Rule 8.10(2) of the Listing Rules.

Ms. Shen has more than two decades of experience in corporate consultancy and equity investment areas. Ms. Shen served as the chief operating officer and partner of Shanghai Yashang Enterprise Consulting Co., Ltd. (上海亞商企業諮詢有限公司) from September 2001 to March 2010, responsible for daily operation of, and business negotiations for the company. Since October 2010, Ms. Shen has been serving in the general manager’s office of Shanghai Shengyu Equity Investment Fund Management Co., Ltd. (上海盛宇股權投資基金管理有限公司) (“**Shanghai Shengyu**”), overseeing all healthcare private equity investments and leading strategic sector positioning, deal execution and post-investment management for the company.

Ms. Shen obtained her bachelor’s degree in marketing and her master’s degree in business administration from Zhongnan University of Economics and Law (中南財經政法大學) in June 1998 and June 2001, respectively.

DIRECTORS AND SENIOR MANAGEMENT

Ms. Shen was nominated as the vice president of Jiangsu Association for Medical Devices Industry (江蘇省醫療器械行業協會) since October 2023, with an initial term of five years.

Ms. Shen was a director of the following company and the relevant details are as follows:

Company name	Nature of business before dissolution	Position	Responsibility	Reason for dissolution	Current status and date of dissolution
Shanghai Yuhai Investment Management Co., Ltd (上海宇海投資管理有限公司) (“Shanghai Yuhai”)	Investment management	Director	Overseeing corporate affairs	Cessation of business	Voluntarily deregistered on 11 July 2023

Ms. Shen confirmed that, to the best of her knowledge, (i) the aforesaid deregistered company was solvent immediately prior to its deregistration and had no outstanding claim or liabilities arising from any material non-compliance incidents; (ii) she has not received any notification in respect of penalty, action or proceeding from the PRC authorities as a result of the deregistration; (iii) she is not aware of any actual or potential claim which has been or will be made against her as a result of the deregistration and (iv) Shanghai Yuhai was a company which Shanghai Shengyu, the investment company where Ms. Shen was employed, originally intended to register as a fund manager. Following the termination of such registration plan, Shanghai Yuhai was deregistered without having commenced any business operations. There was no judgment or findings of fraud, dishonesty, any misconduct or wrongful act on Ms. Shen’s part in connection with the dissolution of the above company.

Ms. Shen also held the office on the following company incorporated in the PRC prior to the revocation of its business licence and the relevant details are as follows:

Company name	Nature of business before revocation of business licence	Position	Responsibility	Reason for revocation of business licence	Current status and date of revocation of business licence
Suzhou Shihuikang Information Technology Co., Ltd. (蘇州視惠康信息技術有限公司) (“Suzhou Shihuikang”)	Television health application development	Director	Overseeing corporate affairs	Note	Compulsorily liquidated followed by revocation of business licence on 28 June 2022

Note: The company was deregistered as it was inactive with no substantial business operation. Prior to its respective deregistration, the business licence of the company had been revoked as the company had no substantial business operation and had omitted the requirement of annual inspection.

Ms. Shen confirmed that, to the best of her knowledge, (i) Suzhou Shihuikang was a portfolio company of the investment institution where she was previously employed. Suzhou Shihuikang was compulsorily liquidated due to a rupture in its capital chain. Ms. Shen did not participate in the day-to-day operations and management of Suzhou Shihuikang. There was no wrongful act on her part leading to the revocation of business licence pertinent to the aforesaid company; (ii) the aforesaid company was solvent immediately prior to its revocation of business licence or deregistration and had no outstanding claim or liabilities arising from any material non-compliance incidents; (iii) she has not received any notification in respect of penalty, action or proceeding from the PRC authorities as a result of the revocation of business licence or deregistration; and (iv) she is not aware of any actual or potential claim which has been or will be made against her as a result of the revocation of business licence or deregistration.

Mr. Chen Gao (陳杲先生), aged 33, is our non-executive Director. Mr. Chen joined us in June 2020 and is responsible for supervising our overall development. In addition to his directorship with our Company, Mr. Chen is also an incumbent director of the following companies: (i) Zhejiang Kefa Capital Management Co., Ltd. (浙江科發資本管理有限公司) since January 2017; (ii) Beijing Shihan Centennial Culture Media Co., Ltd. (北京世瀚百年文化傳媒有限公司) since February 2017; (iii) Ningbo Meishan Bonded Area Jiarun Information Consulting Co., Ltd. (寧波梅山保稅港區嘉潤信息諮詢有限公司) since July 2023; (iv) Ningbo Meishan Bonded Area Kebao Information Consulting Co., Ltd. (寧波梅山保稅港區科寶信息諮詢有限公司) since August 2024; (v) Zhejiang Prohealth Technology

DIRECTORS AND SENIOR MANAGEMENT

Co., Ltd. (浙江普羅亨健康科技有限公司) since December 2017; (vi) Hangzhou Zhike Venture Capital Management Co., Ltd. (杭州之科創業投資管理有限公司) since January 2021; and (vii) Hangzhou Chuangqiao Information Technology Co., Ltd. (杭州創喬信息技術有限公司) since July 2019.

Mr. Chen obtained his bachelor’s degree in economics and finance and his master’s degree in finance from The University of Melbourne, Australia in December 2014 and December 2016, respectively.

Mr. Chen was a director of the following company and the relevant details are as follows:

Company name	Nature of business before dissolution	Position	Responsibility	Reason for dissolution	Current status and date of dissolution
Hangzhou Chuangke Yuanzhi Technology Co., Ltd. (杭州創科遠致科技有限 公司) (“Chuangke Yuanzhi”) . .	Software development	Director	Providing strategic guidance	Cessation of business	Voluntarily deregistered on 12 May 2025

Mr. Chen confirmed that, to the best of his knowledge, (i) the aforesaid deregistered company was solvent immediately prior to its deregistration and had no outstanding claim or liabilities arising from any material non-compliance incidents; (ii) he has not received any notification in respect of penalty, action or proceeding from the PRC authorities as a result of the deregistration; (iii) he is not aware of any actual or potential claim which has been or will be made against him as a result of the deregistration and (iv) Chuangke Yuanzhi was a portfolio company of the investment institution where Mr. Chen was previously employed. The company was compulsorily liquidated due to a rupture in its capital chain. Mr. Chen did not participate in the day-to-day operations and management of Chuangke Yuanzhi. There was no judgment or findings of fraud, dishonesty, any misconduct or wrongful act on Mr. Chen’s part in connection with the dissolution of the above company.

Independent Non-executive Directors

Dr. Cheng Zengjiang (程增江先生), aged 60, is our independent non-executive Director. Dr. Cheng joined us in January 2026 and is responsible for supervising and providing independent judgement to our Board. Dr. Cheng is the chairman of our Remuneration Committee and a member of each of our Audit Committee and our Nomination Committee.

Dr. Cheng served as the general manager of Beijing Sipu Run’an Medicine Technology Co., Ltd. (北京思普潤安醫藥科技有限公司) from April 2006 to December 2006, and as the R&D director of Hainan Sihuan Pharmaceutical Co., Ltd. (海南四環醫藥有限公司), a subsidiary of Sihuan Pharmaceutical Holdings Group Ltd. (四環醫藥控股集團有限公司), the shares of which are listed on the Stock Exchange (stock code: 0460) from April 2009 to April 2012. In addition to his directorship with our Company, Dr. Cheng is incumbent in the following companies: (i) the chairman of Kebeiyuan (Beijing) Biopharmaceutical Technology Co., Ltd. (科貝源(北京)生物醫藥科技有限公司) since January 2007; (ii) an independent non-executive director of BrightGene Bio-Medical Technology (Suzhou) Co Ltd (博瑞生物醫藥(蘇州)股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 688166) since 27 September 2024; (iii) an independent director of Chengdu Easton Bio Pharmaceuticals Co., Ltd. (成都苑東生物製藥股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 688513) since December 2024; and (iv) an independent non-executive director of Suzhou Zelgen Bio-pharmaceuticals Co., Ltd. (蘇州澤璟生物製藥股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 688266) since May 2025.

Dr. Cheng obtained his bachelor’s degree in pharmacy from The Second Military Medical University (中國人民解放軍第二軍醫大學) (currently known as The Naval Medical University (中國人民解放軍海軍軍醫大學)) in July 1986. Dr. Cheng obtained his master’s degree and doctorate’s degree in medicine and pharmaceutical analysis from the Academy of Military Medical Sciences of the People’s Liberation Army Academy of Military Sciences (中國人民解放軍軍事科學院軍事醫學研究院) in August 1991 and in July 1997, respectively.

DIRECTORS AND SENIOR MANAGEMENT

Dr. Cheng was a director of the following company and the relevant details are as follows:

Company name	Nature of business before dissolution	Position	Responsibility	Reason for dissolution	Current status and date of dissolution
Beijing Tongxieyi Investment Management Co., Ltd. (北京同寫意投資管理有限公司) (“Tongxieyi”)	Investment management	Legal representative, executive director and manager	Providing strategic guidance	Cessation of business	Voluntarily deregistered on 14 November 2025
Beijing Premium Enterprise Pharmaceutical Technology Co., Ltd. (北京高端偉業醫藥科技有限公司) (“Beijing Premium”) . . .	Pharmaceutical technology	Vice chairman of the board	Providing strategic guidance	Cessation of business	Voluntarily deregistered on 25 May 2018

Dr. Cheng confirmed that, to the best of his knowledge, (i) each of the aforesaid deregistered companies was solvent immediately prior to its deregistration and had no outstanding claim or liabilities arising from any material non-compliance incidents; (ii) he has not received any notification in respect of penalty, action or proceeding from the PRC authorities as a result of the deregistration; (iii) he is not aware of any actual or potential claim which has been or will be made against him as a result of the deregistration and (iv) Dr. Cheng did not participate in the day-to-day operations and management of Tongxieyi and Beijing Premium. There was no judgment or findings of fraud, dishonesty, any misconduct or wrongful act on Dr. Cheng’s part in connection with the dissolution of the above companies and the dissolution of the above companies were due to the above companies’ own voluntary decision to cease business.

Ms. Zhu Zhaoxia (朱朝霞女士) aged 50, is our independent non-executive Director. Ms. Zhu joined us in January 2026 and is responsible for supervising and providing independent judgement to our Board. Ms. Zhu is the chairwoman of our Audit Committee and a member of our Nomination Committee.

Ms. Zhu has more than two decades of experience in financial realms. Ms. Zhu commenced her career as a practising auditor at Ernst & Young Hua Ming LLP (安永華明會計師事務所) from September 2001 to August 2003. She subsequently served as the management controller of L’Oréal (China) Co., Ltd. (歐萊雅(中國)有限公司). Ms. Zhu then successively served as the finance department manager and the regional finance manager of Reckitt Benckiser Home (China) Co., Ltd. (利潔時家化(中國)有限公司) from February 2008 to August 2014. From August 2014 to April 2020, Ms. Zhu served as the finance director of Greater China region of Mundi Pharma (China) Co., Ltd. (萌蒂(中國)製藥有限公司). Ms. Zhu has been serving as a partner of HMRX Consulting (Beijing) Co., Ltd. (合美睿信(北京)管理諮詢有限公司) since May 2024.

Ms. Zhu obtained her bachelor’s degree in accounting from Xi’an Jiaotong University (西安交通大學) in July 1998, and her master’s degree in accounting from Shanghai University of Finance and Economics (上海財經大學) in February 2001. Ms. Zhu was certified as a certified public accountant by the Office of the CPA Examination Committee of the Ministry of Finance (財政部註冊會計師考試委員會) in February 2000.

Mr. Chai Jinshan (柴金山先生), aged 50, is our independent non-executive Director. Mr. Chai joined us in 13 January 2026 and is responsible for supervising and providing independent judgement to our Board. Mr. Chai is a member of our Audit Committee and a member of our Remuneration Committee.

From November 2006 to June 2014, Mr. Chai consequently served as the R&D director and general manager of the medical information division of Shenzhen Chuangjie Technology Co., Ltd. (深圳市創捷科技有限公司). Mr. Chai served as the R&D department manager from November 2006 to July 2009, then as the R&D director from July 2009 to May 2011, and finally as the general manager of the healthcare information division from May 2011 to June 2014. After leaving the said company, Mr Chai served as the general manager of Shenzhen Shenmingtai Technology Co., Ltd (深圳深銘泰科技有

DIRECTORS AND SENIOR MANAGEMENT

限公司) from March 2016 to November 2020. Subsequently, Mr. Chai served as the vice general manager of Topsec Technologies Group Inc. (天融信科技集團股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 002212).

Mr. Chai obtained his bachelor’s degree in applied physics from the University of Science and Technology of China (中國科學技術大學) in July 1999.

Mr. Chai obtained his project manager certificate (項目經理資格證書) issued by the Office of Certification for the Qualification of Computer Information System Integration of the Ministry of Industry and Information Technology (中華人民共和國工業和信息化部計算機信息系統集成資質認證工作辦公室) in April 2004. Mr. Chai was also certified as an Information Systems Integration and Services Project Manager (信息系統集成及服務項目管理人員) by China Information Technology Industry Federation (中國電子信息行業聯合會) in July 2015. Additionally, Mr. Chai was certified as an information security professional (註冊信息安全專業人員) by China Information Technology Security Evaluation Centre (中國信息安全測評中心) in September 2025.

SENIOR MANAGEMENT

Our senior management is responsible for the day-to-day management of our daily business operations and the implementation of our business strategies adopted by our Board.

For the biographical details of **Dr. Wang** (our chief executive officer), **Dr. Zhang Guiping** (the vice president of our R&D department) and **Mr. Li Jiapeng** (the vice president of our R&D department), see “— Board of Directors”.

Apart from Dr. Zhang Guiping and Mr. Li Jiapeng, **Dr. Mike Liu, Dr. Wang Haidan** (汪海丹博士) and **Mr. Liu Guidong** (劉桂東) are also the key members of senior management team. The following table sets out certain information of each of the said three senior management team members:

Name	Age	Position(s)	Principal roles and responsibilities	Date of joining our Group	Date of appointment as senior management member	Relationship with other Directors senior management members
Dr. Mike Liu . . .	60	Chief business officer	Market expansion and managing the business partnerships of our Group and assisting our Chairman in terms of developing our business strategies	July 2020	July 2020	None
Dr. Wang Haidan (汪海丹博士). .	48	Chief medical officer	Managing and supervising the clinical trials of our Group	June 2022	June 2022	None
Mr. Liu Guidong (劉桂東先生). .	50	Head of finance and the secretary of our Board	Managing the financial functions of our Group and assisting on the matters pertinent to the operation of our Board	September 2021	September 2021 April 2025	None

Dr. Mike Liu, aged 60, is our chief business officer. Dr. Liu joined us in July 2020. Dr. Liu is responsible for managing market expansion and business partnerships of our Group, and at the same time assisting Dr. Wang in terms of developing our business strategies.

Dr. Liu has extensive experiences in technology licensing partnerships, business development, market expansion, and biopharmaceutical R&D realms. From May 2001 to August 2005, Dr. Liu served as the licensing and business development manager of Purdue Pharma L.P., the United States. From September 2005 to November 2010, Dr. Liu served as associate Director of global commercial development for Alexion Pharmaceuticals Inc., the United States. Dr. Liu returned to China in 2010 and subsequently participated in global business development activities at Jiangsu Hengrui Pharmaceuticals Company Ltd. (江蘇恒瑞醫藥股份有限公司) (stock codes: 1276 and 600276.SH). From May 2018 to June 2020, Dr. Liu served as the senior vice president of Jiangsu Alphamab Biopharmaceuticals Co., Ltd (江蘇康寧傑瑞生物製藥有限公司), a company listed on the Stock Exchange (stock code: 9966).

DIRECTORS AND SENIOR MANAGEMENT

Dr. Liu obtained his bachelor’s degree in biochemistry from Nanjing University (南京大學) in June 1988 and his doctorate’s degree in biochemistry from University of Nebraska Medical Center, the United States in May 1995. Dr. Liu also obtained his master of business administration from The University of Washington, the United States in May 2001.

Dr. Wang Haidan (汪海丹博士), aged 48, is our chief medical officer. Dr. Wang joined us in June 2022, and is responsible for managing and supervising the clinical trials of our Group.

Dr. Wang has more than two decades of experience in pharmaceutical industry. Dr. Wang commenced his career as a practicing physician at the First Affiliated Hospital of the Fourth Military Medical University (第四軍醫大學第一醫院) from July 2005 to March 2009. Dr. Wang subsequently served as the senior staff officer at the Beijing Centre for Adverse Drug Reaction Monitoring (北京市藥品不良反應檢測中心) from April 2009 to March 2011. From April 2011 to May 2025, Dr. Wang served as a submission manager of Shanghai Nuohua Trade Co., Ltd. (上海諾華貿易有限公司). Dr. Wang worked at R&G Pharma Studies Co., Ltd. (諾思格(北京)醫藥科技股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 301333) from May 2015 to April 2017. From April 2017 to March 2019, Dr. Wang served as the senior medical director of Shenzhen Salubris Pharmaceuticals Co., Ltd. (深圳信立泰藥業股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 002294). From March 2019 to February 2021, Dr Wang served as the senior director of the clinical development department of Shanghai Mingju Biotechnology Co., Ltd. (上海明聚生物科技股份有限公司). From January 2021 to June 2022, Dr. Wang served as the vice president of the business division of Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd. (北京抗創聯生物製藥技術研究有限公司), a wholly-owned subsidiary of CSPC Pharmaceutical Group Limited (石藥集團), which is listed on the Stock Exchange (stock code: 1093). In addition to the aforesaid employment, Dr. Wang also served as a senior expert of Guangdong Pharmacovigilance Union (廣東藥物警戒聯盟) from 2018 to 2022.

Dr. Wang obtained his medical practitioner licence (醫藥資格證書) issued by Beijing Municipal Health Bureau (北京市衛生局) (currently known as Beijing Municipal Health Commission (北京市衛生健康委員會)) in December 2009. Dr. Wang was recognised as a “2023 Jiangsu Innovation and Entrepreneurship Talent (2023年江蘇省“雙創”人才) jointly by Jiangsu Provincial Party Committee’s Leading Group Office (江蘇省委人才工作領導小組辦公室) and Jiangsu Provincial Department of Science and Technology (江蘇省科學技術廳) in December 2023. Notably, Dr. Wang is one of the core members of the “2023 Gusu Major Innovation Team” (2023 姑蘇重大創新團隊).

Dr. Wang obtained his bachelor’s degree in clinical medicine and master’s degrees in oncology from the Fourth Military Medical University (中國人民解放軍第四軍醫大學) (also known as Air Force Medical University (中國人民解放軍空軍軍醫大學)) in July 2002. Dr. Wang obtained his doctorate’s degree in internal medicine from the same university in July 2005.

Mr. Liu Guidong (劉桂東先生), aged 50, is our head of finance and the secretary of our Board. Mr. Liu joined us in September 2021, responsible for overall financial management of our Company, and assisting on the matters pertinent to the operation of our Board.

Mr. Liu has more than two decades of experience in accounting and finance areas. Mr. Liu commenced his career as the general ledger accountant of Beijing Zhongji Asia-Pacific Trading Co., Ltd. (北京中基亞太貿易有限公司) in July 1998 and served the company till May 2001. From June 2001 to October 2005, Mr. Liu worked at Bayer Guangyi Panels Co., Ltd. (拜耳光翌板材有限責任公司). From November 2005 to September 2014, Mr. Liu served as senior finance manager of Syngenta Seeds (Beijing) Co., Ltd (先正達種苗(北京)有限公司). From September 2014 to November 2019, Mr. Liu worked at Mundi Pharma (China) Co., Ltd. (萌蒂(中國)製藥有限公司). From December 2019 to August 2021, Mr. Liu served as chief financial officer of Guangzhou YuHeng Biotechnology Co., Ltd. (廣州譽衡生物科技股份有限公司).

Mr. Liu obtained his bachelor’s degree in accounting from Beijing Jiaotong University (北京交通大學) in July 1998. Mr. Liu obtained his master’s degree in business administration at New York Institute of Technology, the United States in May 2023.

DIRECTORS AND SENIOR MANAGEMENT

Mr. Liu obtained his advanced diploma in accounting and business from the Association of Chartered Certified Accountants in June 2017. He became a fellow member of the Chartered Global Management Accountant, the qualification of which was jointly conferred upon by the Chartered Institute of Management Accountants and the Institute of Management Accountants in December 2017. Mr. Liu also became a fellow member of the Institute of Public Accountants, Australia, and a fellow member of the Institute of Financial Accountants, the United Kingdom, in July 2020. Additionally, Mr. Liu obtained his Intermediate Accountant Certificate issued by the Ministry of Human Resources and Social Security of the PRC (中華人民共和國國家人力資源和社會保障部) and the Ministry of Finance of the PRC (中華人民共和國財政部) in September 2024.

Directors’ and Senior Management’s Interests

Save as disclosed above, none of our Directors or senior management members has been a director of any public company the securities of which are listed on any securities market in Hong Kong or overseas in the three years immediately preceding the date of this document.

Save as disclosed above, to the best of the knowledge, information and belief of our Directors, having made all reasonable enquiries, there was no other matter with respect to the appointment of our Directors that needs to be brought to the attention of our Shareholders and there was no information relating to our Directors that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules as of the Latest Practicable Date.

As of the Latest Practicable Date, save for the interests in the Shares held by Dr. Wang, which are disclosed in “Statutory and General Information — E. Disclosure of Interests — Interests of our Directors” set out in Appendix IV to this document, none of our Directors held any interest in the securities within the meaning of Part XV of the SFO.

JOINT COMPANY SECRETARIES

Ms. Zheng Weihua (鄭偉華女士), has been appointed as one of our joint company secretaries on 13 January 2026 with effect immediately prior to the [REDACTED]. Ms. Zheng joined us in September 2025 as the deputy director of board affairs and the assistant to our Chairman. Prior to joining our Group, Ms. Zheng worked at Suzhou Oppl Lighting Co., Ltd. (蘇州歐普照明股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 603515) from July 2017 to June 2018. Ms. Zheng served as the investor relations manager of Kintor Pharmaceutical Limited (開拓藥業有限公司), a company listed on the Stock Exchange (stock code: 9939) from June 2018 to May 2024. From May 2024 to October 2024, Ms. Zheng served as the senior manager of the office of the board of directors of Star Plus Legend Holdings Limited (巨星傳奇集團有限公司), a company listed on the Stock Exchange (stock code: 6683). From October 2024 to September 2025, Ms. Zheng served as the senior manager of office of the board of directors of Kedi Biomedical (Wuxi) Co., Ltd. (科笛生物醫藥(無錫)有限公司), which is one of the subsidiaries of Cutia Therapeutics, a company listed on the Stock Exchange (stock code: 2487).

Ms. Zheng obtained her bachelor’s degree in accounting from Wuhan University of Technology (武漢理工大學) in June 2014, and her master of public administration from Wuhan University (武漢大學) in June 2017, respectively.

Ms. Zheng obtained her accounting professional qualification jointly issued by the Ministry of Human Resources and Social Security of the PRC (中華人民共和國人力資源和社會保障部) and the Ministry of Finance of the PRC (中華人民共和國財政部) in September 2019. Ms. Zheng also obtained her Board Secretary Certificate issued by Shenzhen Stock Exchange in November 2023.

Mr. Chow Tsz Ho (周梓浩先生), has been appointed as one of our joint company secretaries on 13 January 2026 with effect immediately prior to the [REDACTED]. Mr. Chow has approximately seven years of experience in company secretarial profession. He is an assistant manager of the listing services department of TMF Hong Kong Limited, a company providing corporate accounting and corporate secretarial services in Hong Kong.

Mr. Chow obtained his bachelor’s degree in business administration from Hong Kong Shue Yan University (香港樹仁大學) in July 2018. Mr. Chow is an associate member of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom.

DIRECTORS AND SENIOR MANAGEMENT

KEY EMPLOYMENT TERMS

We normally enter into (i) an employment contract, and (ii) a confidentiality agreement with our senior management members and other key personnel, and our staff is required to follow our corporate policies. Below sets out the key terms of these contracts we enter into with our senior management and other key personnel, which they are required to comply with.

Confidentiality

- *Scope of confidential information.* Confidential information includes but not limited to: technical proposals, design schemes, manufacturing methods, formulas, salary parameters, process flows, technical indices, R&D records, technical reports, inspection reports, experimental data, test results, drawings (including sketches), survey data, clinical trial data, improved machinery and equipment, samples, prototypes, models, moulds, operation manuals, technical documents, related correspondence, official documents, customer information, marketing plans, procurement data, pricing policies, financial data and supply channels.
- *Confidential obligation.* Except as required for the performance of duties, the employee shall not disclose, inform, publish, transfer, or in any way cause any third party to become aware of any technical secrets or other business secret information belonging to our Company, nor use such secret information for any purpose beyond the scope of employment duties.
- *Confidential period.* The employee shall strictly comply by the confidentiality obligation during employment. Even after resignation, confidentiality obligation remain in effect until either we publicly announce declassification or the information has entered the public domain.

DIRECTORS’ REMUNERATION

For the details of the service contracts that we have entered into with our Directors, see “Statutory and General Information — C. Further Information about our Directors and Senior Management — 1. Particulars of the Services Contracts” set out in Appendix IV to this document.

The aggregate amount of fees, salaries, wages and bonus, pension cost-defined contribution plan, other social security costs and housing benefits and share-based compensation expenses we paid to our Directors in respect of the years ended 31 December 2024 and 2025, and the five months ended 31 May 2026 were RMB5.9 million, RMB5.2 million and RMB44.8 million, respectively. Further information on the remuneration of each Director during the Track Record Period is set out in Note 9 in the Accountant’s Report set out in Appendix I to this document.

During the Track Record Period, no remuneration was paid to our Directors as an inducement to join or upon joining our Group. No compensation was paid or payable to our Directors, past Directors during the Track Record Period for the loss of office as director of any member of our Group or of any other office in connection with the management of the affairs of any member of our Group. None of our Directors waived any emoluments during the Track Record Period.

Under the arrangements currently in force, the aggregate amount of remuneration (excluding share-based payment and excluding any discretionary bonus which may be paid) payable by our Group to our Directors for the year ended 31 December 2026 is expected to be approximately RMB2.4 million.

For the years ended 31 December 2024 and 2025, and the five months ended 31 May 2026, the five highest paid individuals of our Group included two Directors, three Directors and three Directors, and the aggregate amount of fees, salaries, allowances and retirement benefits scheme contributions we paid to the highest paid individuals who are neither Directors nor chief executives of our Company were RMB6.6 million, RMB4.5 million and RMB13.2 million, respectively.

During the Track Record Period, no remuneration was paid to the five highest paid individuals of our Company as an inducement to join or upon joining our Company. No compensation was paid or payable to such individuals during the Track Record Period for the loss of any office in connection with the management of the affairs of any member of our Company.

DIRECTORS AND SENIOR MANAGEMENT

CORPORATE GOVERNANCE

We have established the following 3 committees in our Board of Directors: an Audit Committee, a Nomination Committee, a Remuneration Committee. Each of the said committee operates in accordance with terms of reference established by our Board.

Audit Committee

We have established an Audit Committee with written terms of reference in compliance with Rule 3.21 of the Listing Rules and the Code of Corporate Governance and Corporate Governance Report in Appendix C3 to the Listing Rules. Our Audit Committee consists of three independent non-executive Directors, namely, Ms. Zhu Zhaoxia, Dr. Cheng Zengjiang and Mr. Chai Jinshan, with Ms. Zhu Zhaoxia being the chairwoman of our Audit Committee, holds the appropriate professional qualifications as required under Rules 3.10(2) and 3.21 of the Listing Rules. The primary duties of our Audit Committee are to assist our Board by providing an independent view of the effectiveness of our financial reporting process, internal control and risk management systems, overseeing the audit process and performing other duties and responsibilities as assigned by our Board.

Remuneration Committee

We have established a Remuneration Committee with written terms of reference in compliance with Rule 3.25 of the Listing Rules and the Code of Corporate Governance and Corporate Governance Report in Appendix C3 to the Listing Rules. Our Remuneration Committee consists of two independent non-executive Directors and one executive Director, namely, Dr. Cheng Zengjiang, Dr. Wang and Mr. Chai Jinshan, with Dr. Cheng Zengjiang being the chairman of our Remuneration Committee. The primary duties of our Remuneration Committee include, but are not limited to, the following: (i) making recommendations to our Board on our policy and structure for all remuneration of Directors and senior management and on the establishment of a formal and transparent procedure for developing the policy on such remuneration; (ii) determining the specific remuneration packages of all Directors and senior management; and (iii) reviewing and approving performance-based remuneration by reference to corporate goals and objectives resolved by our Board from time to time.

Nomination Committee

We have established a Nomination Committee with written terms of reference in compliance with the Code of Corporate Governance and Corporate Governance Report in Appendix C3 to the Listing Rules. Our Nomination Committee consists of two independent non-executive Directors and one executive Director, namely, Dr. Wang, Ms. Zhu Zhaoxia and Dr. Cheng Zengjiang, with Dr. Wang being the chairman of our Nomination Committee. The primary duties of our Nomination Committee include, without limitation, reviewing the structure, size and composition of our Board, assessing the independence of independent non-executive Directors and making recommendations to our Board on matters relating to the appointment of Directors.

Diversity

We are committed to promoting the culture of diversity in our Company. We have strived to promote diversity to the extent practicable by taking into consideration a number of factors in our corporate governance structure.

We have adopted a board diversity policy which sets out the objective and approach to achieve and maintain diversity of our Board in order to enhance the effectiveness of our Board. Pursuant to our board diversity policy, we seek to achieve Board diversity through the consideration of a number of factors, including but not limited to gender, age, cultural background, educational background, industry experience and professional experience. Our Directors have a balanced mix of knowledge and skills, including knowledge and experience in the areas of pharmaceutical and medical industry, business management, accounting and general corporate administration. They obtained degrees in various majors including chemistry, clinical medicine, accounting, and business administration. Furthermore, the ages of our Board range from 33 to 60. We have also taken, and will continue to take steps to promote gender diversity at all levels of our Company, including but without limitation at our Board and the management levels. While we recognise that the gender diversity at our Board level can be improved given its current composition of predominantly male directors, we will continue to apply the principle

DIRECTORS AND SENIOR MANAGEMENT

of appointments based on merits with reference to our diversity policy as a whole. We aim to maintain the current gender ratio of our Board following [REDACTED]. We have taken and will continue to take steps to promote and enhance gender diversity at all levels of our Company, including but not limited to at our Board and senior management levels. We will also ensure that there is gender diversity when recruiting staff at mid to senior level. It is our objective to maintain an appropriate balance of gender diversity with reference to the stakeholders’ expectation and international and local recommended best practises.

Our Nomination Committee is delegated by our Board to be responsible for compliance with relevant codes governing board diversity under the Corporate Governance Code. After the [REDACTED], our Nomination Committee will review our board diversity policy from time to time to ensure its continued effectiveness and we will disclose in our corporate governance report about the implementation of our board diversity policy on an annual basis.

Corporate Governance Code

We aim to achieve high standards of corporate governance which are crucial to our development and safeguard the interests of our Shareholders. To accomplish this, we expect to comply with the Corporate Governance Code set out in Appendix C1 to the Listing Rules and the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Listing Rules after the [REDACTED], save for the deviation from the code provision C.2.1 of the Corporate Governance Code.

Pursuant to code provision C.2.1 of the Corporate Governance Code, the roles of chairman and chief executive officer should be separated and should not be performed by the same individual. Nonetheless, having considered the nature and extent of our operations, and Dr. Wang’s familiarity with the operations of our Group, that all major decisions are made in consultation with members of our Board and relevant Board committees, and that there are three independent non-executive Directors on our Board offering independent perspectives, our Directors are therefore of the view that there are adequate safeguards in place to ensure sufficient balance of powers and authorities between our Board and the management of our Company and that it is in the best interest of our Group to have Dr. Wang taking up both roles notwithstanding the provision of C.2.1 of the Corporate Governance Code.

COMPLIANCE ADVISER

We have appointed Red Solar Capital Limited as our compliance adviser (“**Compliance Adviser**”) upon the [REDACTED] pursuant to Rule 3A.19 of the Listing Rules. The material terms of the Compliance Adviser’s agreement are as follows: (i) Red Solar Capital Limited shall act as our Compliance Adviser for the purpose of Rule 3A.19 of the Listing Rules for a period commencing on the [REDACTED] and ending on the date on which we comply with Rule 13.46 of the Listing Rules in respect of our financial results for the first full financial year commencing after the [REDACTED], or until the agreement is terminated, whichever is earlier; (ii) our Compliance Adviser will provide us with certain services, including proper guidance and advice as to compliance with the requirements under the Listing Rules and applicable laws, regulations and rules; (iii) our Compliance Adviser will, as soon as reasonably practicable, inform us of any amendment or supplement to the Listing Rules announced by the Stock Exchange from time to time, and of any amendment or supplement to the applicable laws, regulations and rules in Hong Kong applicable to our Company; (iv) our Compliance Adviser will act as an additional channel of communication of our Company with the Stock Exchange; and (v) we must consult with and, if necessary, seek advice from our Compliance Adviser on a timely basis in the following circumstances: (1) before the publication of any regulatory announcement, circular or financial report; (2) where a transaction, which might be a notifiable or connected transaction, is contemplated including share issues, sales or transfers of treasury shares and share repurchases; (3) where we propose to use the [REDACTED] of the [REDACTED] in a manner different from that detailed in this document or where the business activities, developments or results of our Company deviate from any forecast, estimate, or other information in this document; and (4) where the Stock Exchange makes an inquiry under Rule 13.10 of the Listing Rules.

DIRECTORS AND SENIOR MANAGEMENT

COMPETITION

Each of our Directors confirms that as of the Latest Practicable Date, he/she did not have any interest in a business which competes or is likely to compete, directly or indirectly, with our business and requires disclosure under Rule 8.10 of the Listing Rules. See “Relationship with our Group of Controlling Shareholders”.

CONFIRMATION FROM OUR DIRECTORS

Rule 3.09D of the Listing Rules

Each of our Directors confirms that he or she (i) has obtained the legal advice referred to under Rule 3.09D of the Listing Rules in December 2025 and (ii) understands the requirements under the Listing Rules that are applicable to him or her as a director of a [REDACTED] issuer under the Listing Rules and the possible consequences of making a false declaration or giving false information to the Stock Exchange.

Rule 3.13 of the Listing Rules

Each of the independent non-executive Directors has confirmed (i) his/her independence as regards each of the factors referred to in Rules 3.13(1) to (8) of the Listing Rules, (ii) he/she has no past or present financial or other interest in the business of our Company or our subsidiaries or any connection with any core connected person of our Company under the Listing Rules as of the Latest Practicable Date and (iii) that there are no other factors that may affect his/her independence at the time of his/her appointment.

Rule 13.51 of the Listing Rules

To the best of the knowledge, information and belief of our Directors having made all reasonable enquiries, there was no information relating to the appointment of our Directors that is required to be disclosed pursuant to paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules or any other matters concerning any Director that needs to be brought to the attention of our Shareholders as of the Latest Practicable Date.